Palvella Therapeutics Inc (PVLA)

02:00 AM

Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MyChesCo

02:00 AM

Feb 05, 2025

This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Feb 05, 2025

Feb 05, 2025

TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target -February 05, 2025 at 07:50 am EST - Marketscreener.com

Feb 05, 2025

Feb 05, 2025

TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - MarketBeat

Feb 05, 2025

Feb 05, 2025

Cowen initiates Palvella Therapeutics with buy, $44 target By Investing.com - Investing.com UK

Feb 05, 2025

Jan 27, 2025

Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment - MSN

Jan 27, 2025

Jan 24, 2025

Research Analysts Issue Forecasts for PVLA FY2025 Earnings - Defense World

Jan 24, 2025

Jan 14, 2025

Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease - MSN

Jan 14, 2025

Jan 13, 2025

Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at HC Wainwright - Defense World

Jan 13, 2025

Jan 10, 2025

Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease - Investing.com India

Jan 10, 2025

Jan 10, 2025

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies - The Manila Times

Jan 10, 2025

Jan 10, 2025

Palvella Therapeutics Announces Publication of Results from - GlobeNewswire

Jan 10, 2025

Jan 08, 2025

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations - The Manila Times

Jan 08, 2025

Jan 08, 2025

Palvella Therapeutics Announces First Patients Dosed in - GlobeNewswire

Jan 08, 2025

Jan 08, 2025

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN - The Bakersfield Californian

Jan 08, 2025

Jan 06, 2025

Brokers Issue Forecasts for PVLA FY2029 Earnings - Defense World

Jan 06, 2025

Jan 05, 2025

Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN

Jan 05, 2025

Jan 04, 2025

Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at HC Wainwright - Defense World

Jan 04, 2025

Dec 31, 2024

Palvella Therapeutics registers 5.6M shares by selling holders - MSN

Dec 31, 2024

Dec 30, 2024

Analysts Issue Forecasts for PVLA FY2024 Earnings - Defense World

Dec 30, 2024

Dec 28, 2024

What is HC Wainwright’s Estimate for PVLA Q4 Earnings? - Defense World

Dec 28, 2024

Dec 27, 2024

Palvella Therapeutics initiated with a Buy at H.C. Wainwright - Yahoo Finance

Dec 27, 2024

Dec 27, 2024

Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at HC Wainwright - Defense World

Dec 27, 2024

Dec 26, 2024

Palvella Therapeutics stock gains attention with Phase 3 trial data expected in early 2026 - Investing.com Canada

Dec 26, 2024

Dec 22, 2024

Pieris Pharmaceuticals: Q1 Earnings Snapshot - Marketscreener.com

Dec 22, 2024

Dec 21, 2024

Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - MSN

Dec 21, 2024

Dec 19, 2024

Palvella therapeutics director George Jenkins acquires $51,720 in shares By Investing.com - Investing.com Canada

Dec 19, 2024

Dec 19, 2024

Palvella therapeutics director George Jenkins acquires $51,720 in shares - Investing.com

Dec 19, 2024

Dec 19, 2024

Pieris Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com

Dec 19, 2024

Dec 19, 2024

Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Marketscreener.com

Dec 19, 2024

Dec 19, 2024

Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo

Dec 19, 2024

Dec 18, 2024

Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com

Dec 18, 2024

Dec 18, 2024

Palvella Therapeutics closes on Pieris merger; completes nearly $80M private placement - Pennsylvania Business Report

Dec 18, 2024

Dec 16, 2024

After losing AstraZeneca collab, Boston biotech opts for reverse merger - The Business Journals

Dec 16, 2024

Dec 16, 2024

Main Line biotech firm completes reverse merger, raises $78.9 million - The Business Journals

Dec 16, 2024

Dec 15, 2024

Palvella Therapeutics Closes Merger with Pieris Pharmaceuticals - citybiz

Dec 15, 2024

Dec 15, 2024

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com

Dec 15, 2024

Dec 14, 2024

Pieris Pharmaceuticals: Q3 Earnings Snapshot - Marketscreener.com

Dec 14, 2024

Dec 14, 2024

PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com

Dec 14, 2024

Dec 14, 2024

Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Dec 14, 2024

Dec 13, 2024

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million - The Manila Times

Dec 13, 2024

Dec 13, 2024

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent - The Bakersfield Californian

Dec 13, 2024

Dec 13, 2024

Palvella Therapeutics Announces Closing of Merger with - GlobeNewswire

Dec 13, 2024